The CDTI SICC Innvierte of Innovation invests, along with three coinversores, Aortyx, S.L. in today's bioabsorbible patch to reduce the mortality rates for dissection aórtica

Aortyx, medical devices company based in Barcelona, has erected 13.8 million euros in a number to get your patch aórtico bioabsorbible to the first clinical trials within two years. Among investors is the CDTI, through their SICC Innvierte, participates in their joint investment initiative, accompanying professional private investors, previously authorised by Innvierte, delegating the management of participation in the company. The operation was conducted with Ship2B Ventures through BSocial Impact Fund, FESE and BSocial Impact FESE, S.A. and NARA HEALTH CAPITAL I, F.C.R. and the input of CDTI Innovation is €2,070,000.

Aortyx has developed a solution to address the dissection aórtica that is minimally invasive provide lasting results. The company has designed a swinging catheter which crosses the aorta and displays a patch bioabsorbible who also serves as a support to foster the growth of new tissue. The technology now has been tested successfully in animals and bodies.

The objective of this round of funding is to achieve the first clinical trials within two years.

The patch bioabsorbible of Aortyx and minimally invasive implementation could transform the treatment of aórticas dissection, saving thousands of lives every year in europe.

AORTYX, S.L.

Aortyx is a pioneer company founded in 2018 by three researchers of IQS School of Engineering: Jordi Martorell, Noemí Balà, Salvador Borrós, and the chief of vascular surgery department of Hospital clínic of Barcelona, Dr Vicenç Riambau.

The company was born the desire of the founders to apply their knowledge in engineering biomechanics a problem with the greatest possible impact on the improvement of medical care.

Through advances, Aortyx is already under way to develop a comprehensive, effective and lasting solution that respects the nature of the most important artery of the body.

Ship2B Ventures

Ship2B Ventures is a venture capital that invests in impact startups in early stage that seek to respond to major challenges of our society: the health and quality of life of vulnerable groups, and climate change.

Impact as investors seek to generate a triple profitability: economic, social and environmental policies. Combining the best of the world of venture capital with the world in order to maximize the impact of financial profitability of investments with a clear intent to generate, manage and measure its impact.

The operation of joint investment with the CDTI Aortyx innovation via the BSocial Impact Fund, FESE and BSocial Impact FESE, S.A.

NARA HEALTH CAPITAL I, F.C.R.:

Nara Capital management is a private capital invested in Biopharma businesses and HealthTech from technology transfer of research centres. Nara invests in projects and disruptive transformers in their initial stages of research and development.

This operates using its in-depth knowledge of the sector to incorporate capital and operational capacities to startups, with the dual aim to generate long-term value their investors and create a positive impact on health and quality of life of patients and of society.

Innvierte

Innvierte is an initiative aimed at promoting the entrepreneurial innovation through support to the risk capital investment in technology-based enterprises or innovative programme. This is done through the collective investment type closed Innvierte Sustainable Economy SICC S.M.E., S.A., self-managed and under the supervision of the national Values and that the CDTI Innovation is a shareholder Only.

To date, the CDTI innovation has committed 2,183 M €in 57 investment vehicles that have invested in more than 602 companies, and through its joint investment line directly committed an amount of 632 M €in 188 businesses.

Innvierte fits into the strategy for science, technology and innovation 2021-2027, adopted by decision of the council of ministers, in september. This 2020 Strategy contains goals, the reforms and measures to be taken throughout the area of r + D + i in order to boost their growth and impact, and is one of the pillars on which the design of the government's policy in r + D + i for the coming years.

CDTI Innovation

The centre for technological development and innovation, CDTI E.P.E. is the agency for innovation of the ministry of science, innovation and universities, whose goal is the promotion of technological innovation in business. The CDTI mission is to ensure that the business fabric english generates and transform knowledge into growth científico-técnico globally competitive, sustainable and inclusive. By 2024, within the framework of a new strategic plan, the CDTI provided more than $2.3 billion euros of support for business startups and spain.

More information:

Office of the press
prensa@cdti.es
91-581.55.00

On The Internet
Website:www.cdti.es
In Linkedin:https :// www.linkedin.com/company/cdti/
X:https :// x.com/CDTI _ innovation
On Youtube:https :// www.youtube.com/user/CDTIoficial

Aortyx, S.L.:
Website:https :// aortyx.com/
In LinkedIn:https :// www.linkedin.com/company/aortyx/

Ship2B Ventures:
Website:https :// www.ship2bventures.com/
In LinkedIn:https :// www.linkedin.com/company/ship2b-ventures/
X:https :// x.com/Ship2BVentures

NARA HEALTH CAPITAL I, F.C.R.:
Website:https :// www.nara.capital/
In LinkedIn:https :// www.linkedin.com/company/naracapital/